Chemotherapy Section, Rizzoli Orthopedic Institute, Bologna, Italy.
Cancer. 2011 Apr 15;117(8):1731-5. doi: 10.1002/cncr.25718. Epub 2010 Nov 8.
Periosteal osteosarcoma is a rare variant of osteosarcoma. Wide surgical removal is the mainstay of treatment, but controversy remains about the role of chemotherapy. The objective of this study was to review and analyze the clinical and treatment-related factors that influence the survival of patients with periosteal osteosarcoma who received treatment in a single institution.
Thirty-three patients with periosteal osteosarcoma (19 males and 14 females) with a median age of 16 years (range, ages 6-32 years) underwent surgery (32 patients) and received radiotherapy (1 patient). Chemotherapy was received according to different regimens for high-grade osteosarcoma by 14 patients who had grade 3 tumors.
The 10-year overall survival rate was 84%. The only patient who did not undergo surgery died of disease after 9 months; for the remaining 32 patients the 10-year disease-free survival rate was 65%. Survival was not influenced by the receipt of chemotherapy. The patients who received chemotherapy had a 10-year overall survival rate of 86%, and those who received only local treatment had an overall survival rate of 83% (P = .73).
The authors' experience indicated that the treatment of periosteal osteosarcoma requires only wide surgical removal of the tumor and that adjuvant chemotherapy does not improve survival.
骨膜骨肉瘤是骨肉瘤的一种罕见亚型。广泛的外科切除是主要的治疗方法，但化疗的作用仍存在争议。本研究旨在回顾和分析单一机构治疗的骨膜骨肉瘤患者的临床和治疗相关因素对生存的影响。
33 例骨膜骨肉瘤患者（男 19 例，女 14 例），中位年龄 16 岁（年龄 6-32 岁），32 例行手术治疗，1 例行放射治疗。根据 14 例 3 级肿瘤患者的高级骨肉瘤不同方案接受化疗。
10 年总生存率为 84%。唯一未行手术的患者在 9 个月后因疾病死亡；其余 32 例患者的 10 年无病生存率为 65%。化疗的接受与否不影响生存。接受化疗的患者 10 年总生存率为 86%，仅接受局部治疗的患者总生存率为 83%（P =.73）。
作者的经验表明，骨膜骨肉瘤的治疗仅需要广泛的肿瘤切除，辅助化疗并不能提高生存率。
